Tech Company Financing Transactions
Replimune Funding Round
On 9/11/2017, Replimune raised $55 million in Series B investment from Foresite Capital, Atlas Venture and Bain Capital Life Sciences.
Transaction Overview
Company Name
Announced On
9/11/2017
Transaction Type
Venture Equity
Amount
$55,000,000
Round
Series B
Investors
Proceeds Purpose
These funds will also enable us to establish in house GMP manufacturing capabilities in preparation for the later stage clinical development and commercialization of our products.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
500 Unicorn Park Dr. 3rd Floor
Woburn, MA 01801
USA
Woburn, MA 01801
USA
Phone
Website
Email Address
Overview
Oncolytic immunotherapy is an emerging class of cancer therapeutics which exploit the ability of viruses to selectively replicate in and kill tumor tissue, while at the same time inducing a potent, patient-specific, anti-tumor immune response.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Philip Sparke
Chief Executive Officer
Robert Coffin
Chief Operating Officer
Colin Love
VP - Bus. Development
Pamela Esposito
Browse more venture capital transactions:
Prev: 9/11/2017: Petal venture capital transaction
Next: 9/12/2017: Pegasus Solar venture capital transaction
Share this article
About Database of VC Transactions
We do our best to document every notable VC transaction. VC transactions reported here are derived from company press releases and news coverage. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs